FDA Agrees that La Jolla Pharmaceutical Has Sufficient Data for Investigational New Drug Application

The U.S. Food and Drug Administration has agreed that La Jolla Pharmaceutical Co. has enough data to support an investigational new drug application for a drug that treats patients ...

Riboxx Pharma collaborates with CNBG to evaluate potential of Riboxxim TLR3 agonist

By PBR Staff Writer Riboxx Pharmaceuticals and China National Biotec Group (CNBG) jointly announced that they have started a research collaboration to evaluate Riboxxim, a TLR3 agonist ...

Dr. Reddy’s labs launches generic Zometa in US

By PBR Staff Writer India-based global pharmaceutical company Dr. Reddy’s Laboratories has launched Zoledronic Acid injection (4 mg/5 mL), following the approval of its abbreviated ...

Teva to begin new Laquinimod Phase III trial

The first patient has been enrolled for the third Phase III trial of the oral multiple sclerosis treatment. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Active ...

Gov. Herbert supportive of bill banning smoking in cars with children

By Lisa Riley Roche SALT LAKE CITY — Gov. Gary Herbert said he sees the need for a bill banning smoking in cars when there are child passengers that has passed the 2013 Legislature. “I ...

China Destroyed Ikea, Kraft and Nestle Products for Violations at End of 2012

BY NEWS DESK  The Chinese government destroyed incoming products from three food giants – Ikea, Kraft and Nestle – at the end of 2012 for violations of food quality standards, ...

Silence Therapeutics gets German approval for cancer drug trial

(Reuters) – Biotech research and development company Silence Therapeutics said it received approval from German authorities for trials of its pancreatic cancer drug and was reviewing ...

FDA panel advises calcitonin salmon not be used for osteoporosis

(Reuters) – A panel of advisers to the Food and Drug Administration recommended on Tuesday that the agency no longer support the marketing of calcitonin salmon as a treatment ...

U.S. drugmaker admits misbranding AIDS appetite medicine

(Reuters) – Par Pharmaceutical Cos, a generic drugmaker, has pleaded guilty to improperlymarketing a medication intended to address appetite loss in AIDS patients, and agreed ...

Ex-InterMune CEO Harkonen’s Wire-Fraud Conviction Upheld

By Karen Gullo Ex-InterMune Inc. (ITMN) Chief Executive Officer W. Scott Harkonen’s fraud conviction for disseminating misleading information about a drug’s clinical trial was ...

Targacept, AstraZeneca amend terms of collaboration

By Matt Evans Targacept Inc. and AstraZeneca, a pharmaceutical industry partner that has licensed and funded some of Targacept’s drug discovery efforts, have amended their ...

White House urges Congress: “let FDA spend user fees”

By LYNNE TAYLOR With the US Food and Drug Administration (FDA) set to lose about 9% of its budget for fiscal 2013 as part of the $85.3 billion automatic federal spending cuts – ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS